×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Shionogi reports data from Phase III portion of Covid-19 drug trial
Clinical Trials Arena
Shionogi announced that ensitrelvir, a Covid-19 drug, met primary and secondary endpoints in the Phase III segment of SCORPIO-SR study.
2 months ago
Recognized with the Double A List for Leadership in Corporate Transparency and Performance on Climate Change ...
Shionogi Inc.
D.) is pleased to announce that it has been recognized for its leadership in corporate transparency and performance on Climate Change and Water...
2 months ago
Japan's Shionogi eyes early 2025 for U.S. release of COVID pill
Nikkei Asia
OSAKA -- Japanese drugmaker Shionogi expects to be able to sell its Xocova COVID-19 treatment in the U.S. in early 2025, part of a focus on...
1 month ago
When Will New COVID-19 Antivirals Be Approved in the U.S.? | TIME
Time Magazine
COVID-19 antivirals like simnotrelvir and ensitrelvir seem to work for more people than Paxlovid. But they're not approved in the U.S..
3 months ago
Shionogi (TSE:4507) sheds 3.9% this week, as yearly returns fall more in line with earnings growth
Simply Wall Street
Buying a low-cost index fund will get you the average market return. But if you invest in individual stocks, some are...
1 week ago
Shionogi Strengthens Regulatory Leadership with the Appointment of Dr. Ramón Polo as Senior Vice President, Head ...
Business Wire
Dr. Polo's diverse expertise includes overseeing clinical development operations, pharmacovigilance programs and regulatory strategies. He joins...
2 months ago
SHIONOGI's Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Government, and ...
Shionogi Inc.
Release Date: March 11, 2024. In November 2023, an antimicrobial drug for drug-resistant infections developed by SHIONOGI was selected as the first drug...
1 month ago
Shionogi, Fronteo developing AI diagnostic support models for dementia, depression
BioWorld MedTech
Shionogi & Co. Ltd. is partnering with Fronteo Inc. to develop artificial intelligence (AI)-based diagnostic tools to diagnose mental and...
2 months ago
Generative AI turns conference attendees into infectious disease warriors
Medical Marketing and Media
The photobooth-meets-generative-AI experience from Shionogi transformed conference attendees into soldiers outfitted in Roman armor.
3 months ago
Shionogi to acquire Qpex Biopharma for $140m
Pharmaceutical Technology
Shionogi has signed a definitive agreement for the acquisition of Qpex Biopharma in a deal valued at approximately $140m.
9 months ago